The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trialJason J. Luke, Paul A. Moore, Girish Mallesara et al.|Nature Medicine|2023Cited by 135
Business as unusual: medical oncology services adapt and deliver during <scp>COVID</scp>‐19Avraham Travers, James Lynam, Kim Adler et al.|Internal Medicine Journal|2021Cited by 9
Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)Fiona Day, Jarad Martin, Swetha Sridharan et al.|BMC Cancer|2022Cited by 6
Mortality within 30 days of immunotherapy (checkpoint inhibitors) in metastatic cancer patients treated at Australian tertiary cancer center.Hiren Mandaliya, Girish Mallesara, Sang Kim et al.|Journal of Clinical Oncology|2019Cited by 5
The impact of integrating an oncology nurse practitioner into an acute care hospital emergency department: An Australian tertiary cancer centre experience.Gillian Blanchard, Hiren Mandaliya, Antonino Bonaventura et al.|Journal of Clinical Oncology|2020Cited by 2